[肠道微生物群作为免疫检查点抑制剂的潜在生物标志物]
Yuki Ozaki1, Yoshiki Suzuki, Hiroyuki Suzuki
1Dept. of Chest Surgery, Fukushima Medical University.
Gan to kagaku ryoho. Cancer & chemotherapy
|October 27, 2024
概括
肠道微生物群的组成可能会影响免疫检查点抑制剂 (ICI) 对非小细胞肺癌 (NSCLC) 的有效性. 为了更好的ICI生物标志物,需要对肠道,肺部和瘤微生物群进行进一步的研究.
科学领域:
- 在瘤学瘤学.
- 微生物组研究 微生物组研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫检查点抑制剂 (ICI) 是非小细胞肺癌 (NSCLC) 的标准治疗方法.
- PD-L1阳性是传统的生物标志物,但在PD-L1阴性病例中观察到有效性.
- 作为ICI疗效的潜在生物标志物,正在研究宿主和瘤因素.
研究的目的:
- 探索肠道微生物群在预测NSCLCICI治疗疗效方面的作用.
- 研究肺和瘤微生物群作为ICI反应的潜在生物标志物.
- 为了确定与改善ICI治疗结果相关的特定微生物物种.
主要方法:
- 对接受抗PD-1抗体治疗的NSCLC患者肠道微生物组合的分析.
- 使用实时PCR识别特定细菌物种.
- 对肠道,肺部和瘤微生物群以及ICI疗效的现有文献的审查.
主要成果:
- 特定的肠道微生物组合与增强的ICI有效性有关.
- 抗生素的使用可能会降低ICI的疗效,而便微生物群移植显示出潜在的疗效.
- 初步分析确定了与治疗反应积极相关的特定细菌物种.
结论:
- 肠道微生物群的组成是NSCLCICI治疗中生物标志物开发的一个有希望的领域.
- 肺部和瘤微生物群的多样性也可能与ICI疗效相关.
- 对宿主 (肠道) 和瘤微环境微生物群的综合分析对于未来的生物标志物发现至关重要.
相关概念视频
01:22Introduction to the Human Microbiota
Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity, and disease...
01:27The Oral Microbiota
The oral microbiome includes a complex ecosystem comprising over 700 microbial species, identified through genomic sequencing and culture-based analyses to date. This community includes a core microbiome, found universally among individuals, and a variable component influenced by environmental factors such as diet, lifestyle, and host genetics. Site-specific conditions, including oxygen gradients, pH levels, and nutrient availability, determine the spatial distribution of these microorganisms...
01:18Functions of the Gut Microbiota
The gut microbiota includes trillions of microorganisms that colonize the human gastrointestinal tract, including bacteria, archaea, viruses, and fungi. This complex ecosystem plays a critical role in maintaining intestinal and systemic health. Most of these microbes inhabit the large intestine, establishing a relatively stable and diverse community that contributes to gut homeostasis through various metabolic, immunological, and protective mechanisms.Dominant bacterial phyla, such as...
01:18Dysbiosis of the Gut Microbiota
The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
01:22Gut-Brain Axis
The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such as...
01:21Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...